dactolisib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Dactolisib is an imidazoquinoline derivative acting as a PI3K inhibitor. It also inhibits mTOR. It is being investigated as a possible cancer treatment.   Wikipedia

Chemistry

  • SMILES: CN1C(=O)N(c2ccc(cc2)C(C)(C)C#N)c3c1cnc4ccc(cc34)c5cnc6ccccc6c5
  • InChIKey: JOGKUKXHTYWRGZ-UHFFFAOYSA-N
  • Mol. Mass: 469.55
  • ALogP: 5.89
  • ChEMBL Molecule:
    dactolisib  
More Chemistry

Pharmacology

Alternative names

2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile | 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile | bez235 | bez-235 | dactolisib | nvpbez235 | nvp bez235 | nvp-bez235 | nvp-bez235-nx

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Breast Neoplasms (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Endometrial Neoplasms (Phase 2)

Hamartoma Syndrome, Multiple (Phase 1)

Kidney Neoplasms (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Lung Diseases (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)

Respiratory Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue